endpoint & Cmed’s New Integration
endpoint Clinical, the global interactive response technology (IRT) company, and Cmed Technology, the technology division of a full-service CRO with its encapsia clinical data suite, announced a new interoperability in their clinical trial software systems. This integration allows the power of IRT to be accessed through eSource.
The new technology offering was designed by connecting endpoint’s technology platforms, PULSE and DRIVE, with Cmed’s new dedicated web app, Inventory, furthering the scope of its third generation clinical data suite encapsia.
As the complexities of clinical trials steadily increase, endpoint and Cmed are dedicated to enhance their technologies further to minimize the burden on site staff and provide them with an optimal “consumer-like” experience.
For more information , www.endpointclinical.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
